Phase IB-II, Open Label, Multicenter Feasibility Study of Pazopanib in Combination With Paclitaxel and Carboplatin in Patients With Platinum-Refractory/Resistant Ovarian, Fallopian Tube or Peritoneal Carcinoma
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Pazopanib (Primary) ; Carboplatin; Paclitaxel
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 11 Aug 2017 The study has been Restarted in Spain.
- 15 Jan 2017 This trial was suspended in Spain, according to European Clinical Trials Database.
- 11 Oct 2016 Planned number of patients changed from 96 to 88.